| Menopausal syndrome
Veozah vs Lynkuet
Side-by-side clinical, coverage, and cost comparison for menopausal syndrome.Deep comparison between: Veozah vs Lynkuet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLynkuet has a higher rate of injection site reactions vs Veozah based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lynkuet but not Veozah, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Veozah
Lynkuet
At A Glance
Oral
Daily
NK3 receptor antagonist
Oral
Daily
NK1/NK3 receptor antagonist
Indications
- Menopausal syndrome
- Menopausal syndrome
Dosing
Menopausal syndrome 45 mg tablet orally once daily with or without food.
Menopausal syndrome 120 mg (two 60 mg capsules) orally once daily at bedtime, with or without food; swallow capsules whole.
Contraindications
- Known cirrhosis
- Severe renal impairment or end-stage renal disease
- Concomitant use with CYP1A2 inhibitors
- Pregnancy (exposure may cause pregnancy loss or stillbirth)
Adverse Reactions
Most common (>=2%) Abdominal pain, diarrhea, insomnia, back pain, hot flush, hepatic transaminase elevation
Serious Hepatic transaminase elevation and hepatotoxicity
Postmarketing Serious drug-induced hepatotoxicity with elevated transaminases, alkaline phosphatase, and bilirubin, coupled with fatigue, nausea, pruritus, jaundice, pale feces, and dark urine
Most common (>=2%) headache, fatigue, dizziness, somnolence, abdominal pain, rash, diarrhea, muscle spasms
Serious CNS depressant effect and daytime impairment, hepatic transaminase elevations
Pharmacology
Fezolinetant is an NK3 receptor antagonist that blocks neurokinin B binding on kisspeptin/neurokinin B/dynorphin neurons to modulate neuronal activity in the thermoregulatory center, with >450-fold selectivity for NK3 over NK1 or NK2 receptors.
Elinzanetant is an NK1 and NK3 receptor antagonist that inhibits Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, modulating neuronal activity in thermoregulation associated with hot flashes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Veozah
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (10/12)
Lynkuet
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (5/12)
UnitedHealthcare
Veozah
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (6/8)
Lynkuet
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Veozah
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Lynkuet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Veozah.
No savings programs available for Lynkuet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VeozahView full Veozah profile
LynkuetView full Lynkuet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.